Tuuli Ranki

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

Anniina Koski, Lotta Kangasniemi, Sophie Escutenaire et al. · Molecular Therapy · 2010 · 251 citations · Full text

Medicine, Immunology, Oncology +17

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Tuuli Ranki, Sari Pesonen, Akseli Hemminki et al. · Journal for ImmunoTherapy of Cancer · 2016 · 202 citations · Full text

Pharmacy, Immunology, Oncology +17

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi et al. · Cancer Research · 2012 · 138 citations · Full text

Medicine, Immunology, Oncology +17

Tissue-Specific Promoters Active in CD44+CD24−/low Breast Cancer Cells

Gerd Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi et al. · Cancer Research · 2008 · 109 citations

Medicine, Cancer Biology, Oncology +16

Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

Mari Raki, Anna Kanerva, Ari Ristimäki et al. · Gene Therapy · 2005 · 85 citations

Medicine, Molecular Biology, Oncology +12